Arcturus Therapeutics Holdings (ARCT) Stock News

ARCT-810 showed safety and biomarker improvements in OTC deficiency. LUNAR 2.0 platform demonstrated >30-fold protein expression improvement in NHP studies. Company plans to integrate ARCT-2601 into Phase 2 study by year-end. Also acquiring AI discovery company myNEO.

Arcturus Therapeutics announced that its LUNAR 2.0 platform produced greater than 30-fold higher protein expression in multiple non-human primate studies, expanding potential mRNA therapeutic applications.

Arcturus Therapeutics announced that its Phase 2 study of ARCT-810 showed the drug is generally safe and well tolerated, with encouraging activity across key urea cycle biomarkers.

Arcturus Therapeutics announced interim Phase 2 data for its OTC deficiency treatment and introduced the LUNAR 2.0 next-generation mRNA delivery platform. No further details were disclosed in the initial report.